to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers

Luye Pharma Group Ltd.40 enrolled

Overview

The purpose of this study is to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers.

This is an open-label study in healthy volunteers to evaluate the safety, tolerability and pharmacokinetics of four formulations of LY03009 (F1, F2, F3, F4) after a single intramuscular injection. Approximately 40 healthy subjects are planned to be enrolled in this study and assigned to four cohorts (F1, F2, F3, F4) sequentially, 10 subjects per group at a fixed dose of 112 mg for F1\~F3 and 224 mg for F4. Each subject will receive only one dose in this study.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Parkinson's Disease

Interventions

LY03009 F1DRUG

a single dose of LY03009 F1

LY03009 F2DRUG

a single dose of LY03009 F2

LY03009 F3DRUG

a single dose of LY03009 F3

LY03009 F4

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria： To participate in the study, subjects must meet all of the following inclusion criteria: 1. Willing and capable of giving signed written informed consent; 2. Male or female, 18-65 years of age (inclusive) at screening; 3. Body mass index (BMI, weight \[kg\]/height \[m\]2) between 18.0 and 30.0 kg/m2, inclusive; 4. The screening results within the normal range or outside the normal range but assessed as clinically non-significant by the Investigator based on detailed medical history, clinical laboratory tests, vital signs, physical examination, and 12-lead ECG; QTcF ≤450 msec for male subjects, and QTcF ≤470 msec for female subjects. 5. Males who are willing to remain abstinent; or if engaging in sexual intercourse with a female partner of childbearing potential, willing to use a condom in addition to having the female partner use a highly effective method of contraception throughout the study and until at least 3 months after the end of the study. This requirement does not apply to subjects in a same sex relationship or subjects with female partners of non-childbearing potential. Male subjects must also be willing to not donate sperm throughout the study and until at least 3 months after the end of the study. Exclusion Criteria： Subjects meeting any of the following criteria will be excluded from the study: 1. With history of history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, neurologic, bronchopulmonary, immunologic, and/or lipid metabolism disorders, and/or drug hypersensitivity, or any other condition that, in the opinion of the PI, would jeopardize the safety of the subject, affect the validity of the study results, or impair the ability to provide informed consent; 2. Hospital admission or major surgery within 3 months prior to screening, or plan to have surgery before the completion of study; 3. Receipt of another investigational product within 1 month or 5 half-lives of the other investigational product, whichever is longer, before study drug administration in this study; 4. Unwillingness or inability to comply with food and beverage restrictions during study participation; 5. Have a history of significant drug sensitivity or drug allergy, or known hypersensitivity to the study drugs, the metabolite or formulation excipients; 6. Malignancy within 5 years of screening visit (excluding non-melanoma skin cancer and cervical carcinoma in situ that has been completely resected); 7. Subject who is considered unsuitable for participating in the study in the opinion of investigator. 8. Recent administration of live vaccine within 3 months prior to dosing and until at least 30 days after the completion of the study.

Locations (1)

CMAX clinical Research Pty Ltd

Adelaide, South Australia, Australia

Outcomes

Primary Outcomes

Frequency of adverse events

Frequency of adverse events. Apply to cohort F1, cohort F2 and cohort F3.

Time frame: From screening up to day 98

Frequency of adverse events

Frequency of adverse events. Apply to cohort F4.

Time frame: From screening up to day 161

Secondary Outcomes

Maximum (peak) plasma concentration (Cmax) of LY03009

Maximum (peak) plasma concentration (Cmax) of LY03009. Apply to cohort F1, cohort F2 and cohort F3.

Time frame: From screening up to day 98

Maximum (peak) plasma concentration (Cmax) of LY03009

Maximum (peak) plasma concentration (Cmax) of LY03009. Apply to cohort F4

Time frame: From screening up to day 161

Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-t) of LY03009

Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-t) of LY03009.Apply to cohort F1, cohort F2 and cohort F3.

Time frame: From screening up to day 98

Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-t) of LY03009

Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-t) of LY03009.Apply to cohort F4

Time frame: From screening up to day 161

Area under the plasma concentration-time curve from time zero to infinity (AUC0-∞) of LY03009

Area under the plasma concentration-time curve from time zero to infinity (AUC0-∞) of LY03009.Apply to cohort F1, cohort F2 and cohort F3.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.